What You'll Want to Know About Intercept Pharmaceuticals' Q2 Update
It's fair to say that 2019 isn't going nearly as well as Intercept Pharmaceuticals (NASDAQ: ICPT) shareholders would have liked. The stock is down close to 40% year to date after rising 20% by early April. Intercept's presentation of data from its study of Ocaliva in treating nonalcoholic steatohepatitis (NASH) disappointed many despite overall positive results.
Intercept had an opportunity to impress investors when the company announced its second-quarter results before the market opened on Wednesday. Here's what you need to know from Intercept's Q2 update.
Image source: Getty Images
Quelle Fool.com
